Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
QuintilesIMS
Fish and Richardson
Medtronic
Farmers Insurance
Deloitte
Cipla
McKesson
McKinsey
Healthtrust

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,772,353

« Back to Dashboard

Which drugs does patent 8,772,353 protect, and when does it expire?

Patent 8,772,353 protects OSPHENA and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.
Summary for Patent: 8,772,353
Title:Method for enhancing the bioavalability of ospemifene
Abstract: This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s): Anttila; Markku (Turku, FI)
Assignee: Hormos Medical Ltd. (Turku, FI)
Application Number:13/904,818
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 8,772,353

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE ➤ Try a Free Trial
Duchesnay OSPHENA ospemifene TABLET;ORAL 203505-001 Feb 26, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,772,353

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,236,861 Method for enhancing the bioavailablity of ospemifene ➤ Try a Free Trial
9,855,224 Method for enhancing the bioavailability of ospemifene ➤ Try a Free Trial
8,470,890 Method for enhancing the bioavailability of ospemifene ➤ Try a Free Trial
9,241,915 Method for enhancing the bioavailability of ospemifene ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,772,353

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1713458 ➤ Try a Free Trial
Russian Federation 2385716 ➤ Try a Free Trial
Russian Federation 2006132719 ➤ Try a Free Trial
Portugal 1713458 ➤ Try a Free Trial
Norway 339190 ➤ Try a Free Trial
Norway 20151603 ➤ Try a Free Trial
Norway 337656 ➤ Try a Free Trial
Norway 20063960 ➤ Try a Free Trial
Mexico PA06009274 ➤ Try a Free Trial
Luxembourg 92736 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Mallinckrodt
Johnson and Johnson
Colorcon
Chubb
Covington
Daiichi Sankyo
Merck
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot